You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》微泰醫療(02235.HK)今起招股 入場費3,146.39元
阿思達克 10-06 09:20
提供糖尿病治療及糖尿病監測醫療器械的生物科技企業微泰醫療(02235.HK)公布招股文件,擬於全球發售6,352.95萬股,其中10%於本港作公開發售,每股招股價介乎27.7元至31.15,每手100股,入場費3,146.39元。今日起招股,下周一(11日)截止,預期於同日定價,10月19日掛牌上市。聯席保薦人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人為高盛及中金,聯席賬簿管理人及聯席牽頭經辦人為中信證券。 公司已與基石投資者簽訂投資協議,總投資金額1.54億美元,其中Invesco Advisers, Inc投資3,500萬美元,UBS AM Singapore投資2,500萬美元,LAV Star Limited及LAV Star Opportunities Limited、Springhill Fund及Hudson Bay各投資1,250萬美元,騰訊(00700.HK)全資附屬Tencent Mobility、博裕資本投資管理的Boyu Capital、清池資本(香港)管理的Lake Bleu Prime及Octagon Investments各投資1,000萬美元,OGF、ONH及WWH,及Sage Partners各投資800萬美元。 根據招股價中位數29.43元,公司預期集資淨額為17.5億元,其中31%分配予核心產品,35%分配予持續血糖監測系統,11%分配至第二代貼敷式胰島素泵系統,8%分配至其他產品及在研產品,5%用於建立基於雲端大數據的糖尿病管理平台,其餘10%用於營運資金及其他一般公司用途。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account